Malignant Lung Neoplasm — Trials

Malignant Lung Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

11,122 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,648
Recruiting: 1,431
Ph III recruiting: 179
Growth YoY: +7.9%
Industry share: 37%
Top sponsor: AstraZeneca
Termination share: 34.8%
Trials / 1,000 deaths: 20.1 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,489)

clinicaltrialsPublishedShowing 101–150 of 312 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05256290	Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations	active not recruiting	Phase 1 / Phase 2	200	Black Diamond Therapeutics, Inc.INDUSTRY	1	Jul 22, 2026	clinicaltrials
NCT06003231	A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2	active not recruiting	Phase 2	120	Seagen, a wholly owned subsidiary of PfizerINDUSTRY	7	Jul 22, 2026